Kura Oncology (KURA) Stock Forecast & Price Target

Kura Oncology is making significant strides in the development of targeted therapies for cancer, with a particular focus on the promising drug darolifarnib. The company's strong financial position and partnerships with other companies indicate their commitment to success, and their success in clinical trials further solidifies the potential for their drugs. The use of a new assessment method and promising results in combination with chemotherapy show potential for accelerated approval and potential resistance mutations further validate the potential of this company.

Kura Oncology is facing some challenges with its recently launched menin inhibitor, KOMZIFTI, with slower than expected sales revenue and higher R&D expenses. Despite the higher number of new patient starts and total prescriptions, the company is still facing tough competition in the NPM1-mutant market. Additionally, while Kura has shown efficacy in combination with other therapies, it still needs to address safety concerns, particularly around differentiation syndrome. These challenges suggest a negative outlook for the company's stock in the short term.